NCT04945707View on ClinicalTrials.gov

Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)

PHASE4RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 26, 2021

Primary Completion Date

February 28, 2026

Study Completion Date

May 31, 2026

Conditions
Iron-deficiencyHeart Failure With Preserved Ejection Fraction
Interventions
DRUG

Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]

Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject \<50 kg, 20 mg/kg

DRUG

Placebo

Normal saline

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Pharmacosmos A/S
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Pharmacosmos A/S

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

lead

Massachusetts General Hospital

OTHER

NCT04945707 - Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF) | Biotech Hunter | Biotech Hunter